Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
CytoMed Therapeutics Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
GDTC
Nasdaq
8731
https://www.cytomed.sg/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for CytoMed Therapeutics Ltd
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration
- Mar 20th, 2024 12:30 pm
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
- Mar 18th, 2024 10:00 am
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
- Mar 4th, 2024 10:00 am
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
- Jan 29th, 2024 12:00 pm
One CytoMed Therapeutics Insider Raised Stake By 46% In Previous Year
- Dec 21st, 2023 3:44 pm
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
- Dec 5th, 2023 12:30 pm
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update
- Nov 17th, 2023 2:21 pm
CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
- Nov 14th, 2023 12:47 pm
CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology
- Oct 24th, 2023 5:00 pm
Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology
- Sep 25th, 2023 11:00 am
CytoMed Expands Research Collaboration into China After Entering Into MOU
- Aug 29th, 2023 1:00 pm
CytoMed Therapeutics Limited to Present at the August 24th Virtual Investor Summit
- Aug 17th, 2023 11:30 am
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency
- Aug 15th, 2023 5:00 pm
Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
- Aug 1st, 2023 11:00 am
CytoMed Therapeutics Announces U.S. Patent Granted For its Licensed, Novel CAR-Gamma Delta T Cell Technology
- Jul 27th, 2023 1:00 pm
Insiders Rewarded With S$77k Addition To Investment As CytoMed Therapeutics Stock Hits US$51m
- Jul 14th, 2023 2:52 pm
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US
- Jul 6th, 2023 11:00 am
CytoMed Therapeutics Collaborates With Cancer Treatment Center to Advance Its Unique CAR-T Technology
- Jun 28th, 2023 1:00 pm
CytoMed Therapeutics to Ring Nasdaq Closing Bell
- May 11th, 2023 1:00 pm
CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology
- May 9th, 2023 2:07 pm
Scroll